PepVault
/ database / GLP-1 / GIP / Glucagon Triple Agonist

Retatrutide

Also: Triple-G · GGG agonist

Investigational triple-agonist with the largest weight-loss numbers in early trials.

Evidence
emerging
Legal status
research only
Half-life
~6 days (estimated)
Routes
subq
View on Limitless LifeAdd to compare
What it is

Retatrutide is still in clinical development, but Phase 2 data showed unprecedented average weight loss, exceeding tirzepatide. Long-term safety data is not yet available.

Mechanism

Triple-agonist targeting GLP-1, GIP, and glucagon receptors for additive metabolic effect.

Outcomes it's matched to
Safety

Side-effect profile similar to other GLP-class drugs; long-term data pending.

  • MTC history
  • Pregnancy
  • Use only under physician guidance
Legal context

Not yet approved. Investigational.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault